The Lectin Pathway of the Complement System
The complement system is an essential and powerful component of the innate immune response, acting as a proteolytic cascade that functions in surveillance and defense against pathogens. The system can be activated by three main routes: the classical pathway, the alternative pathway, and the lectin pathway (LP). The lectin pathway is a crucial pattern recognition system that serves as a bridge between innate and adaptive immunity. Unlike the classical pathway, which is typically triggered by antibody-antigen complexes, the lectin pathway is entirely antibody-independent, allowing for an immediate, non-specific response to microbial threats.
The LP is fundamentally homologous in its structure and downstream effects to the classical pathway. The key difference lies in the initiation components. Where the classical pathway uses the C1 complex (C1q, C1r, C1s), the lectin pathway utilizes specific Pattern Recognition Molecules (PRMs) that circulate in the blood, recognizing unique molecular patterns found on the surface of invading microorganisms but not on host cells. This ability to target pathogen-associated molecular patterns (PAMPs) makes the lectin pathway a vital first line of defense.
Components and Pattern Recognition Receptors
The initiation of the lectin pathway relies on a group of circulating PRMs that bind to carbohydrate structures. The primary PRMs are Mannose-Binding Lectin (MBL) and a family of proteins called Ficolins. MBL, also known as Mannan-binding protein (MBP), belongs to the collectin family of proteins, characterized by collagen-like regions and Ca²⁺-dependent carbohydrate recognition domains. MBL forms oligomeric structures (dimers, trimers, tetramers) in the serum, with the tetramer form being the minimum unit generally considered necessary for complement activation.
MBL is highly specific, binding to an array of sugars such as mannose, glucose, N-acetylglucosamine, and fucose when they are arranged in specific patterns (e.g., terminal positions with 3- and 4-OH groups in the equatorial plane). These arrangements are common on the surface of a wide range of microbial pathogens, including various bacterial strains like *Salmonella* and *Listeria*, fungal pathogens such as *Candida albicans*, and viruses like HIV-1 and Respiratory Syncytial Virus (RSV). The Ficolins—specifically M-ficolin, L-ficolin, and H-ficolin (also called ficolin 3 or Hakata antigen)—also act as PRMs, primarily by binding to acetylated residues and other carbohydrate moieties on the pathogen surface.
The PRMs do not act alone. They circulate in the blood complexed with a set of serine proteases known as MBL-Associated Serine Proteases (MASPs). The complex contains three main zymogens: MASP-1, MASP-2, and MASP-3. These MASPs are the effector molecules of the pathway, bearing functional and structural similarities to C1r and C1s of the classical pathway. Also present in the complex are MBL-associated proteins (MAps), such as MAp19 and MAp44, which have regulatory functions.
Mechanism and Enzymatic Cascade
The lectin pathway is triggered when MBL or a Ficolin successfully binds to the specific carbohydrate pattern on the surface of a pathogen. This binding event induces a conformational change in the complex, leading to the auto-activation of MASP-1. Activated MASP-1 then cleaves and activates MASP-2. Once activated, MASP-2 (and to a lesser extent MASP-1) initiates the central cascade by cleaving the next two components in the complement sequence: C4 and C2.
The cleavage of C4 yields two fragments: C4a and C4b. C4b is a large fragment that covalently attaches to the pathogen’s cell membrane near the site of activation. The cleavage of C2 yields C2a and C2b (with C2a historically being the larger, membrane-binding fragment in the classical nomenclature). The membrane-bound C4b then associates with C2a to form the central enzyme complex of the pathway: the C3 convertase (C4b2a). The C3 convertase is the pivotal enzyme that cleaves the most abundant complement protein, C3, into C3a and C3b, leading to a significant amplification of the immune response. C3b fragments are deposited widely on the pathogen surface, acting as a powerful opsonin.
Next, a C3b fragment associates with the C3 convertase (C4b2a) to form the C5 convertase (C4b2a3b). This convertase is responsible for cleaving C5 into C5a and C5b, initiating the terminal common pathway of the complement cascade. C5b then sequentially recruits C6, C7, C8, and multiple C9 molecules, which assemble to form the Membrane Attack Complex (MAC, or C5b-9). The MAC inserts itself into the pathogen’s membrane, creating a large pore that compromises cellular integrity and results in osmotic lysis and the destruction of the microbe.
Effector Functions and Regulation
The lectin pathway achieves pathogen clearance through three main effector functions. The first is direct Lysis of the target cell by the Membrane Attack Complex. The second is Opsonization, where the deposited C3b and C4b fragments coat the pathogen, promoting enhanced attachment and ingestion by phagocytic immune cells. The third is the promotion of Inflammation and Chemotaxis, driven by the small, soluble fragments C3a, C4a, and especially C5a. These fragments, collectively known as anaphylatoxins, are potent inflammatory mediators that trigger mast cell degranulation, increase vascular permeability, and act as chemoattractants to recruit neutrophils and macrophages to the site of infection.
Due to the destructive potential of complement, the lectin pathway must be tightly regulated. Inhibitors ensure that activation is confined to the pathogen surface and does not damage host tissues. Key regulatory molecules include C1-Inhibitor (C1INH), which controls activation by binding to and inactivating MASP-1 and MASP-2. Additionally, MAp44 is a competitive inhibitor that displaces MASP-2 from the MBL complex, preventing the cleavage of C4 and C2. Other key regulators, like Factor H, primarily control the alternative pathway but also influence the deposition and degradation of C3b, helping to maintain immune balance across all pathways.
Clinical Significance and Disease
The lectin pathway is implicated in the pathology of several human diseases, highlighting its critical but sometimes detrimental role in health. Deficiency in MBL, caused by common genetic polymorphisms in the *MBL2* gene, is prevalent in a significant portion of the global population. While this deficiency may not always correlate with clinical symptoms, individuals with very low MBL function are often more susceptible to recurrent bacterial, fungal, and viral infections, particularly those who are immunocompromised or are infants.
Pathological over-activation of the lectin pathway has been linked to numerous conditions. In certain autoimmune disorders, such as rheumatoid arthritis, the MASPs are suggested to play a regulatory role, and their dysregulation may contribute to disease progression. Furthermore, the lectin pathway is an important player in Ischemia/Reperfusion (I/R) injury, where MBL-mediated activation contributes to inflammation and tissue damage following the restoration of blood flow to hypoxic tissue. Most recently, the lectin pathway has been implicated in severe outcomes of COVID-19. MASPs not only initiate complement but are also involved in the coagulation cascade, suggesting that excessive activation of the lectin pathway may contribute to the heightened inflammation and thrombotic complications observed in critically ill patients, making MASP-2 a potential therapeutic target.